Funding

Eleum

Switzerland · Biotech

Eleum develops live biotherapeutics that target gut microbial pathways in ulcerative colitis.

Funding history

Product

Eleum is an EPFL startup project developing bacteria-based therapies intended to restore secondary bile acid production and support the intestinal barrier. Led by Antoine Jalil in Kristina Schoonjans’s laboratory, the team is preparing its approach for clinical development.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
i4L Innogrant for BiotherapeuticsCHF 100KEPFL Startup Launchpad — Participant

Investors

EPFL Startup LaunchpadJoined i4L Innogrant for Biotherapeutics

Coverage

Mar 26, 2026Eleum · i4L Innogrant for Biotherapeutics

Similar companies

ALLOXALLOX combines high-throughput genetics, experimental biology and AI to find functional sites on proteins and develop targeted small-molecule medicines.$10.5M · Seed
Dren BioDren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.$350M · Private financing
BioGeometryBioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.Undisclosed · Series A+
Sourcesactu.epfl.ch ↗